A prospective, non-randomized observational clinical study at University Hospital Zurich, Spital Uster, and Kantonsspital Winterthur collected 261 fluid samples from 184 patients with metastatic solid malignancies. The study focused on feasibility, using current clinical guidelines and patient consent. Techniques included centrifugation, FACS purification, pharmacoscopy, RNA sequencing, mutational profiling, and proteomics analysis. Ethical approval was granted by the Ethics Committee of Kanton Zurich. The study aimed to integrate multi-omics data for precision oncology.